An isocratic reversed-phase liquid chromatograpic assay method was developed for the quantitative determination of atorvastatin and aspirin (ASP) in combined dosage form. A Phenomenex Gemini C-18, 5-μm column with mobile phase containing 0.02 M potassium dihydrogen phosphate-acetonitrile-methanol (30:30:40, v/v/v) adjusted to pH 3 using o-phosphoric acid was used. The flow rate was 1.0 mL min−1 and effluents were monitored at 240 nm. The retention times (RTs) of atorvastatin calcium (ATV) and ASP were 10.5 and 3.8 min, respectively. ATV and ASP stock solutions were subjected to acid and alkali hydrolysis, chemical oxidation, and dry heat degradation. The degraded product peaks were well resolved from the pure drug peak with significant difference in their RT values. Stressed samples were assayed using developed LC method. The proposed method was validated with respect to linearity, accuracy, precision, and robustness. The method was successfully applied to the estimation of ATV and ASP in combined capsule dosage forms.
[1]. S. Budavari 1996 The Merck Index 12th edn Merck & Co. Inc. Whitehouse Station, NJ 897.
[2]. A.E. Gennaro 2000 Remington's — The Science and Practice of Pharmacy 20th edn Mack Publishing Co Easton, PA 1294.
[3]. K. Nakamuara H. Masuda H. Kariyazono J. Arima Y. Iguro K. Yamada R. Sakata 2006 Cytokine 36 201–210.
[4]. V.G. Athyros D.P. Mikahilidis A.A. Papageorgiou V.I. Bouloukos A.N. Pehlivanidis A.N. Symeonidis A.I. Kakafika S.S. Daskalogoulou M. Elisaf 2005 Platelets 16 65–71.
[5]. N. Erk 2003 Anal. Lett. 36 2699–2711.
[6]. H.R. Shen D. Liz M.K. Zhong 2006 Pharmazie 61 18–20.
[7]. J.C. Verd C. Peris M. Alergret C. Diaz Z.G. Hernandez R.M. Sanchez 1999 Brit. J. Pharmacol. 127 1479–1485.
[8]. B.E. Bleske R.A. Willis M. Anthony N. Casselberry M. Datwani V.E. Uhley 2001 Amer. Heart J. 142 262.
[9]. T.G. Altuntas N. Erk 2004 J. Liq. Chromatogr. Relat. Technol. 27 83–93.
[10]. S. Erturk E.S. Aktas L. Ersoy S.J. Ficicioglu 2003 Pharm. Biomed. Anal. 33 1017–1023.
[11]. J.M. McKenney L.S. McCormick S. Weiss M. Koren S. Kafonek D.M. Blanck 1998 Amer. J. Med. 104 137–143.
[12]. X.S. Miao C.D. Metcalfe 2003 J. Chromatogr. A 998 133–141.
[13]. M. Jemal Z. Ouyang B.C. Chen D. Teitz 1999 Rapid Commun. Mass Spectrom. 13 1003–1015.
[14]. W.W. Bullen R.A. Miller R.N. Hayes 1999 J. Amer. Soc. Mass Spectrom. 10 55–66.
[15]. S.S. Yadav D.V. Mhaske A.B. Kakad B.D. Patil S.S. Kadam S.R. Dhaneshwar 2005 Indian J. Pharm. Sci. 67 182–88.
[16]. The British Pharmacopoeia, Vol. I, Her Majesty's Stationery Office, Department of Health, London, 2007, pp, 184–185.
[17]. The United States Pharmacopoeia, Vol. I, United States Pharmacopoeial Convention Inc., Rockville, MD, 2004, pp, 171–74.
[18]. K. Manoj P. Shanmugapandiyan S. Anbazhagan 2004 Indian Drugs 41 284–289.
[19]. Validation of Analytical Procedures: Methodology (Q2R1), International Conference on Harmonization (ICH), Food and Drug Administration, Washington, DC, 1996 & 2005.